EDIT

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates. “In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, toward the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We are highly encouraged by our recent preclinical safety and efficacy data, including emerging data from our GLP toxicology study, as well as data demonstrating EDIT-401’s ability to reduce multiple independent risk factors for atherosclerotic cardiovascular disease, including LDL-C, Lp(a), and ApoB, in non-human primates. Based on these data, we believe EDIT-401 has a potential best-in-class profile as a one-time treatment for hyperlipidemia, and we remain on track to initiate a first-in-human study with early human proof-of-concept data by year end.” Upcoming Data Presentations American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, May 11-15 Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C Pharmacokinetics and Pharmacodynamics of EDIT-401(mu), an In Vivo Gene Editing Therapy for Lowering LDL-C in Mice In vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model TIDES USA 2025: Oligonucleotide & Peptide Therapeutics, May 11-14 Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease 94th European Atherosclerosis Society (EAS) Congress, May 24-27 A Transformative In Vivo C...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Tuesday reported a loss of $25 million in its first quarter. The Cambridge, Massachusetts-based company said it had a loss of 26 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 30 cents per share. The genome editing company posted revenue of $2.8 million in the period, which did not meet Street forecasts. Three analysts surveyed by Zacks expected $8.6 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT

A month has gone by since the last earnings report for Black Diamond (BDTX). Shares have added about 19.3% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Black Diamond due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Black Diamond Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Black Diamond Posts Narrower Q4 Loss Black Diamond did not generate any revenue in the fourth quarter of 2025, consistent with the prior-year period. The company posted an adjusted net loss per share of 14 cents per share, slightly narrower than a loss of 28 cents in the year-ago quarter, reflecting modest improvement in overall profitability. Operating performance during the quarter benefited significantly from lower expenses following restructuring efforts and a sharper focus on core assets. Research and development (R&D) expenses fell nearly 49% to $6.3 million, while general and administrative (G&A) expenses declined about 34% to $4.0 million. These reductions more than offset a $7.3 million non-cash impairment charge related to right-of-use assets and property and equipment. As a result, total operating expenses decreased to $17.6 million from $18.3 million in the prior-year quarter. Other income provided a modest tailwind, with interest income increasing to $1.2 million from $0.6 million, contributing to total other income of $2.5 million versus $2.3 million a year earlier. The company also delivered a slight earnings surprise, driven by improved cost control and a narrower loss base. Although no revenue was recorded in the quarter, full-year FY2025 results included $70 million in license revenue from a strategic agreement with Servier. This upfront payment supported a shift to full-year profitability and strengthened cash flows. Black Diamond continues to streamline its operations and prioritize its lead asset, silevertinib, including out-licensing non-core programs. Management highlighted encouraging early clinical data in EGFR-mutant NSCLC and GBM, with strong response rates observed in phase II studies. Upcoming catalysts include additional NSCLC data readouts and the initiation of a randomized phase II GBM tria...

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. Editasreported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents per share in the year-ago quarter. The comprehensive beat was mainly due to lower operating expenses. Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $24.7 million in the reported quarter, down 19% from the year-ago quarter’s figure. The reported figure, however, comprehensively beat the Zacks Consensus Estimate of $7 million. The year-over-year decrease is primarily due to the recognition of revenues related to milestones achieved under EDIT’s collaboration agreement with Bristol Myers in the year-ago quarter. In the fourth quarter of 2025, R&D expenses decreased 44% to $27.4 million compared with $48.6 million reported in the year-ago period. The decline in R&D expenses is primarily due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by in vivo research and discovery costs. General and administrative expenses were $11.4 million in the reported quarter, down 31% year over year, due to a decrease in employee-related expenses because of reduced workforce and reduced professional service expenses following the abandonment of the reni-cel program. Restructuring and impairment charges fell by $18.5 million to a $6.3 million benefit in the fourth quarter from $12.2 million a year earlier, mainly due to favorable adjustments to previously estimated contract costs tied to the discontinuation of the reni-cel program. Editas had cash, cash equivalents and investments worth $146.6 million as of Dec. 31, 2025, down from $165.6 million as of Sept. 30, 2025. The company expects that its existing cash position will fund operating and capital needs into the third quarter of 2027. In 2025, Editas recorded total revenue...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.” Recent Achievements and Upcoming Milestones Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026. The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026. Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human proof-of-concept data by the end of 2026. Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial with topline data results available in 2027. Upcoming Events Editas Medicine plans to participate in the following investor event: Barclays 28th Annual Global Healthcare Conference Format: Fireside Chat Date: March 12, 2026 Time: 8:30 a.m. ET Miami Beach, FL To...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Monday reported a loss of $5.6 million in its fourth quarter. The Cambridge, Massachusetts-based company said it had a loss of 6 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share. The genome editing company posted revenue of $24.7 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $6.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 8.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Editasreported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 75 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $7.5 million in the reported quarter, up significantly from the year-ago quarter’s figure. The reported figure comprehensively beat the Zacks Consensus Estimate of $2 million. The increase is primarily driven by the recognition of revenues related to a milestone achievement under a collaboration agreement with Bristol Myers. In the third quarter of 2025, R&D expenses decreased 58% to $19.8 million compared with $47.6 million reported in the year-ago period. The downtick in R&D expenses is mainly due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by costs of in vivo research and discovery. General and administrative expenses were $12.3 million in the reported quarter, down 32% year over year, due to a decrease in employee-related expenses resulting from a reduced workforce following the abandonment of the reni-cel program. EDIT did not record any restructuring and impairment charges in the reported quarter. Editas had cash, cash equivalents and investments worth $165.6 million as of Sept. 30, 2025, down from $178.5 million as of June 30, 2025. The company expects that its existing cash position, together with $17.3 million in ATM proceeds raised after Sept. 30, 2025, and retained payments from its Vertex license agreement, will fund operating and capital needs into the third quarter of 2027. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -42.11% due to these changes. Currently, Editas has a nice Growth Score of B, th...

Editas Medicine, Inc. (NASDAQ:EDIT) just released its quarterly report and things are looking bullish. Revenues of US$7.5m beat estimates by a substantial 53% margin. Unfortunately, Editas Medicine also reported a statutory loss of US$0.28 per share, which at least was smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the consensus from Editas Medicine's twelve analysts is for revenues of US$16.0m in 2026, which would reflect a stressful 66% decline in revenue compared to the last year of performance. Losses are predicted to fall substantially, shrinking 50% to US$1.02. Before this latest report, the consensus had been expecting revenues of US$14.6m and US$1.03 per share in losses. See our latest analysis for Editas Medicine There were no major changes to the US$4.00consensus price target despite the higher revenue estimates, with the analysts seeming to believe that ongoing losses have a larger impact on the valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Editas Medicine at US$6.00 per share, while the most bearish prices it at US$1.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bull...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Monday reported a loss of $25.1 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 28 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 38 cents per share. The genome editing company posted revenue of $7.5 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $1.6 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027, enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2025 and provided business updates. “We are incredibly excited by the progress we made in the third quarter advancing our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy designed to significantly reduce LDL cholesterol levels. We recently presented data at AHA and ESGCT demonstrating the ability of EDIT-401 to reduce mean LDL cholesterol levels by over 90 percent in non-human primates,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “In addition, we have extended our cash runway into the third quarter of 2027 and remain on track to submit an investigational new drug or clinical trial application for EDIT-401 by mid-2026, with the goal of achieving in vivo human proof-of-concept data by the end of 2026.” Recent Achievements and Outlook EDIT-401 In September, the Company announced the selection of its lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. In October and November, the Company presented preclinical data at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress and the American Heart Association (AHA) Scientific Sessions 2025. Key findings included: ≥90% LDL-C reduction in non-human primates (NHPs) achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function The ≥90% reduction in LDL-C was achieved with ≥6-fold mean increase in LDLR protein in the NHP liver, requiring only a moderate level of functional editing of LDLR alleles (~10-40%) in the liver LDL-C r...

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 16.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Editas Medicine, Inc. before we dive into how investors and analysts have reacted as of late. Editas reported a loss of 63 cents per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 41 cents. The company had incurred a loss of 82 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $3.6 million in the reported quarter, up significantly from the year-ago quarter’s figure. The reported figure beat the Zacks Consensus Estimate of $1 million. The increase is mainly due to the recognition of revenue related to specified deliverables that were achieved in the second quarter of 2025. In the second quarter of 2025, R&D expenses decreased 70% to $16.2 million compared with $54.2 million reported in the year-ago period. The massive downtick in R&D expenses is mainly due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by costs of in vivo research and discovery. General and administrative expenses were $12.9 million in the reported quarter, down 29% year over year, due to a decrease in employee-related expenses as a result of reduced headcount. Restructuring and impairment charges were $26.1 million in the second quarter of 2025 on account of the discontinuation of the reni-cel program and the related workforce reduction. Editas did not record any restructuring charges in the year-ago quarter. Editas had cash, cash equivalents and investments worth $178.5 million as of June 30, 2025, down from $221 million as of March 31, 2025. The company expects its existing cash, cash equivalents and marketable securities, together with the retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditure into the second quarter of 2027. It turns out, estimates review have trended upward during the past month. Currently...